Literature DB >> 3720181

Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

J D Unadkat, F Bartha, L B Sheiner.   

Abstract

Three models, linked in series, can be used to analyze combined pharmacokinetic (PK) and pharmacodynamic (PD) data arising from non--steady-state experiments. A PK model relates dose to plasma drug concentration (Cp); a link model relates Cp to drug concentration at the effect site (Ce); and a PD model relates Ce to drug effect (E). All three submodels can be stated parametrically. Recently the use of a nonparametric PD submodel has been proposed (CLIN PHARMACOL THER 1984;35:733-41). In this article we use an extended nonparametric approach that represents both the PK and PD models nonparametrically, but retains a parametric link model. Cp data from several PK models and E data from several PD models were simulated. After the addition of noise to both the Cp and E data, they were analyzed by both the parametric and extended nonparametric methods. The methods were compared by how well they estimated the PD model. To assess robustness, the effect of misspecification of the PK submodel on the goodness of estimation of both methods was also compared. In the absence of model misspecification, the parametric method usually estimates the PD model better than the nonparametric method. However, this difference in the performances diminishes and even reverses when the PK model is misspecified. Because one can rarely be certain that model misspecification is absent, the nonparametric approach may offer a distinct advantage for routine analysis of PK/PD data.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3720181     DOI: 10.1038/clpt.1986.143

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  46 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

2.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

3.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

4.  Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.

Authors:  E Bredberg; J Tedroff; S M Aquilonius; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Pharmacodynamic modelling. Application to new drug development.

Authors:  P D Kroboth; V D Schmith; R B Smith
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 6.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

7.  Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers.

Authors:  E Bellissant; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

8.  Investigation of a cellular pharmacodynamic model exhibiting sharp response sensitivity and tolerance.

Authors:  Ronald A Siegel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-12-12       Impact factor: 2.745

Review 9.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

10.  Dose-dependency and time-course of electrophysiologic short-term effects of VIAGRA: a case study.

Authors:  Herbert Jägle; Christine Jägle; Ludwig Sèrey; Lindsay T Sharpe
Journal:  Doc Ophthalmol       Date:  2005 Mar-May       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.